請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46406完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 余家利(Chia-Li Yu) | |
| dc.contributor.author | Han-Wei Lin | en |
| dc.contributor.author | 林漢威 | zh_TW |
| dc.date.accessioned | 2021-06-15T05:07:27Z | - |
| dc.date.available | 2010-09-09 | |
| dc.date.copyright | 2010-09-09 | |
| dc.date.issued | 2010 | |
| dc.date.submitted | 2010-07-26 | |
| dc.identifier.citation | 1. Boyle P, Maisonneuve P, Autier P. Update on cancer control in women. Int J Gynaecol Obstet 2000; 70: 263-303.
2. Pfleiderer A. Diagnosis and staging of ovarian cancer. J Cancer Res Clin Oncol 1984; 107: 81-8. 3. Gonzalez-Diego P, Lopez-Abente G, Pollan M, Ruiz M. Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death. Eur J Cancer 2000; 36: 1816-24. 4. Scully RE, Young RH, Clement PB. Tumors of ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Atlas of tumor pathology, 3rd edn, Washington DC: Armed Forces Institute of Pathology, 1998. 5. Rustin GJ. Tumour markers for ovarian cancer. Eur J Cancer 1992; 28: 2-3. 6. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-16. 7. DiSaia PJ, Bloss JD. Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003; 90(2 Pt 2): S24-32. 8. Malkasian GD Jr, Melton LJ 3rd, O'Brien PC, Greene MH. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 1984; 149: 274-84. 9. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985; 65: 264-70. 10. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4: 1-12. 11. Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995; 76: 2092-6. 12. Pannek J, Partin AW. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Semin Urol Oncol 1998; 16: 100-5. 13. Hunerbein M. The value of tumor markers in colorectal cancer. Recent Results Cancer Res 1998; 146: 48-55. 14. Rubach M, Szymendera JJ, Kaminska J, Kowalska M. Serum CA 15.3, CEA and ESR patterns in breast cancer. Int J Biol Markers 1997; 12: 168-73. 15. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr 2000; 130: 129-32. 16. Antony AC. Folate receptors. Ann Rev Nutr 1996; 16: 501-21. 17. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon C. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand and binding assay. Anal Biochem 2005; 338: 284-93. 18. Elnakat H, Ratnam M. Role of folate receptor genes in reproduction and related cancer. Front Biosci 2006; 11: 506-19. 19. Kane MA, Elwood PC, Portillo RM et al. Influence on immunoreactive folate-binding-proteins of extracellular folate concentration in cultured human cells. J Clin Invest 1988; 81: 1398-406. 20. Miotti S, Bagnoli M, Tomassetti A, Colnaghi MI, Canevari S. Interaction of folate receptor with signaling molecules lyn and Ga13 in detergent-resistant complexes from the carcinoma cell lines. J Cell Sci 2000; 113: 349-57. 21. Sobin LH WC. UICC TNM Classification of Malignant Tumors, 5th edn, New York, New York, Wiley-Liss, 1997. 22. International Federation of Gynecology and Obstetrics: Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1987; 156: 263–64. 23. Mozzetti S, Ferlini C, Concolino P et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005; 11(1): 298-305. 24. Scholler N, Fu N, Yang Y et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in the sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999; 96: 11531-6. 25. Xu Y, Shen Z, Wiper DW et al. Lysophosphatidic acid as a potent biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719-23. 26. Mok SC, Chao J, Skates S et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93: 1458-64. 27. Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic for ovarian cancer. JAMA 2002; 287: 1671-9. 28. Lu KH, Patterson AP, Wang L et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004; 10:3291-300. 29. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000; 82: 1535-8. 30. Huang CY, Cheng WF, Lee CN et al. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res 2006; 26(6C):4721-8. 31. Chen CA, Cheng WF, Lee CN et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol 1999; 74:235-40. 32. Terry KL, Sluss PM, Skates SJ et al. Blood and urinemarkers for ovarian cancer: a comprehensive review. Dis Markers 2004; 20: 53-70. 33. Barlow TS, Przybylski M, Schilder JM, Moore DH, Look KY. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 2006; 16(2): 496-500. 34. Gilani MM, Karimi Zarchi M, Ghaemmaghami F, Behtash N, Mousavi AS, Ansaripoor S. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Gynecol Oncol 2007; 105(3): 780-3. 35. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997; 74:193-8. 36. Ferrandina G, Fagotti A, Salerno MG et al. P53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 1999; 81: 733-40. 37. Ahmed AS, Dew T, Lawton FG et al. Tumor M2-PK as a predictor of surgical outcome in ovarian cancer, a prospective cohort study. Eur J Gynaecol Oncol 2007; 28(2):103-8. 38. Knutson KL, Krco C, Goodman K et al. T cell immunity to folate receptor alpha is prevalent in women with breast or ovary cancer. J Clin Oncol 2006; 24: 4254-61. 39. Antony AC, Verma RS, Unune AR, LaRosa JA. Identification of a Mg2+-dependent protease in human placenta which cleaves hydrophobic folate-binding proteins to hydrophilic form. J Biol Chem 1989; 264: 1911-4. 40. Elwood PC, Deutsch JC, Kolhouse JF. The conversion of the human membrane-associated folate binding protein (folate receptor) to the soluble folate binding protein by a membrane-associated metalloprotease. J Biol Chem 1991; 266: 2346-53. 41. Luhrs CA, Slomiany BL. A human membrane-associated folate binding protein is anchored by a glycosyl-phosphatidylinositol. J Biol Chem 1989; 264: 2146-9. 42. Yang XY, Mackins JY, Li QJ, Antony AC. Isolation and characterization of a folate receptor-directed metalloprotease from human placenta. J Biol Chem 1996; 271(19): 11493-9. 43. Mantovani LT, Miotti S, Menard S et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer 1994; 30A: 363-9. 44. Kalli KR, Oberg AL, Keeney GL et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008; 108(3): 619-26. 45. Hogdall EV, Christensen L, Kjaer SK et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish ‘MALOVA’ Ovarian Cancer Study. Gynecol Oncol 2007; 104: 508-15. 46. Gadducci A, Zola P, Landoni F et al. Serum half-life of CA125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 1995; 58: 42-7. 47. Riedinger JM, Bonnetain F, Basuyau JP et al. Change in CA125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann Oncol 2007; 18: 881-5. 48. Kelemen LE. The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander? Int J Cancer 2006; 119: 246-50. 49. Leamon CP, Low P. Folate-mediated targeting: from diagnosis to drug and gene delivery. Drug Discov Today 2001; 6: 44-51. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46406 | - |
| dc.description.abstract | 目標：
這個研究是為了瞭解漿液性(serous)卵巢癌的病人在臨床病理特徵中α型葉酸接受體(alpha-folate receptor, α-FR)的表現量與病人的預後兩者之間關聯性。 方法： 使用半定量反轉錄聚合酵素連鎖反應(Semi-quantitative reverse-transcription polymerase chain reaction)的方法去偵測91位漿液性卵巢癌病人，其腫瘤組織中α型葉酸接受體(α-FR)表現的程度。除此之外，更分析病人其它臨床病理因素與生物指標，包括國際婦產科聯盟的臨床期別(FIGO stage)、腫瘤惡性程度(tumor grade)、是否接受理想的減積手術(optimal surgery)、淋巴結轉移(lymph nodes metastasis)、術前血清中CA-125的表現量(pre-operative CA-125)以及α型葉酸接受體(α-FR)在癌化組織中的表現量。再將這些結果與病人的無癌症復發期(disease-free interval, DFI)及整體存活率(overall survival, OS)做進一步的分析。 結果： 有4、6、65與16位病人分別位於卵巢癌分期中的第I、第II、第III與第IV期，其中44%的病人受過理想腫瘤減積手術(optimal debulking surgery)治療。末期(stage I: 0.451, stage II: 0.415, stage III: 0.652, 和stage IV: 0.768, p=0.004)或是無法接受理想減積手術(sub-optimal debulking surgery，optimal: 0.490, sub-optimal: 0.766, p=0.003)的病人，其癌症組織中比初期或是接受理想腫瘤減積手術(optimal cyto-reductive surgery)的病人具有明顯較高的α型葉酸接受體表現量。而在預後的分析中，利用多變數分析發現α型葉酸接受體(α-FR)的高表現量對於無癌症復發期(disease-free interval,DFI)是一個明顯的較差的預後因子(HR: 2.70 (1.20-6.05), p=0.016)。對於整體存活率(overall survival,OS)而言則具有邊緣性顯著差異的負面影響(HR: 3.51 (0.93-13.29), p=0.065)。 結論： 漿液性卵巢癌的病人若是在腫瘤檢體上反映出較高的α型葉酸接受體(α-FR)表現量，就可能會有較短的無癌症復發期(disease-free interval, DFI)與整體存活率(overall survival, OS)。因此，α型葉酸接受體(α-FR)對於治療卵巢癌來說可能是一個有發展潛力的生物標記及標靶治療的標的。 關鍵字：α型葉酸接受體、腫瘤抗原標記CA-125、漿液性卵巢癌、存活率 | zh_TW |
| dc.description.abstract | Objectives: To investigate the relationship between alpha-folate receptor (α-FR) expression levels to the clinico-pathologic features and outcomes of patients with serous ovarian carcinoma.
Methods: Semi-quantitative reverse-transcription polymerase chain reaction detected α-FR expression in 91 patients with serous ovarian carcinoma. Clinico-pathologic parameters and biomarkers, including FIGO stage, tumor grade, optimal surgery, lymph nodes metastasis, pre-operative serum CA-125, and α-FR expression levels in cancerous tissues to evaluate disease-free interval (DFI) and overall survival (OS), were analyzed. Results: There were 4, 6, 65, and 16 patients with stages I, II, III, and IV ovarian carcinoma, respectively. Forty (44%) underwent optimal debulking surgery. Patients with advanced stages (stage I: 0.451, stage II: 0.415, stage III: 0.652, stage IV: 0.768, p=0.004) or those with sub-optimal debulking surgery (optimal: 0.490, sub-optimal: 0.766, p=0.003) had significantly higher α-FR expression levels compared to those with early stages or optimal debulking surgery. In prognostic analysis, high α-FR expression level (HR: 2.70 (1.20-6.05), p=0.016) was an independent poor prognostic factor for DFI and had a negative impact on OS with marginal significance (HR: 3.51 (0.93-13.29), p=0.065) using multivariate analyses. Conclusions: Patients of serous ovarian carcinoma with high α-FR expression in cancerous tissue have shorter DFI and OS. α-FR may be a potential biomarker for predicting the outcome of serous ovarian carcinoma patients. Key words: alpha-folate receptor, CA-125, ovarian serous carcinoma, survival | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T05:07:27Z (GMT). No. of bitstreams: 1 ntu-99-P97448005-1.pdf: 518422 bytes, checksum: 013cad3e660f44097134cf45038aab54 (MD5) Previous issue date: 2010 | en |
| dc.description.tableofcontents | 口試委員審定書.........................i
誌謝..................................ii 中文摘要..............................iv 英文摘要..............................vi 第一章 序言............................1 第二章 材料與方法......................3 第三章 實驗結果........................7 第四章 結果與討論.....................10 參考文獻..............................13 附錄 表一..................................20 表二..................................21 表三..................................22 圖一..................................23 圖二..................................24 圖三..................................25 | |
| dc.language.iso | zh-TW | |
| dc.subject | 存活率 | zh_TW |
| dc.subject | α型葉酸接受體 | zh_TW |
| dc.subject | 腫瘤抗原標記CA-125 | zh_TW |
| dc.subject | 漿液性卵巢癌 | zh_TW |
| dc.subject | alpha-folate receptor | en |
| dc.subject | CA-125 | en |
| dc.subject | ovarian serous carcinoma | en |
| dc.subject | survival | en |
| dc.title | α型葉酸接受體的高表現量與漿液性卵巢癌較差存活率相關 | zh_TW |
| dc.title | High Alpha-Folate Receptor Correlates with Poorer Survival in Serous Ovarian Carcinoma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 98-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 鄭文芳(Wen-Fang Cheng) | |
| dc.contributor.oralexamcommittee | 陳祈安(Chi-An Chen) | |
| dc.subject.keyword | α型葉酸接受體,腫瘤抗原標記CA-125,漿液性卵巢癌,存活率, | zh_TW |
| dc.subject.keyword | alpha-folate receptor,CA-125,ovarian serous carcinoma,survival, | en |
| dc.relation.page | 25 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2010-07-27 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
| 顯示於系所單位： | 分子醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-99-1.pdf 未授權公開取用 | 506.27 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。